Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Olema Pharmaceuticals Inc OLMA

Healthcare Biotechnology
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen... see more

Current News (NDAQ:OLMA)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 5, 2026

Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 2, 2025

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

GlobeNewswire November 21, 2025

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 20, 2025

Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock

GlobeNewswire November 19, 2025

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 18, 2025

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

GlobeNewswire November 10, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2025
View More News ››

Opinion & Analysis (NDAQ:OLMA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OLMA)

17.50…

Under the financing, chart is too high...
Form001 - November 21, 2025

Buy buddy buy.

Otherwise FOMO
coolfooldumbguy - November 20, 2025

Something happened….

Only a rumor.....???
Form001 - November 18, 2025

Should go to 35.00 in 2026

Easy. IMO
Form001 - November 5, 2025

Consensus analysts Target 24.38

Now at 8.41....
Form001 - November 4, 2025

Good Time to buy

GLTA
Form001 - November 3, 2025
View more Bullboard ››

Southern Energy Corp.

Southern Energy Corp.

Southern Energy Corp., together with its subsidiaries, operates as an oil and natural gas exploration and production company ...
View More »

Podcasts